减肥药“血拼”中国市场

《财经》杂志
16 Feb

资本市场更关注销售增速,这关乎减肥药离见顶还有多远   文|《财经》记者 辛颖   编辑|王小   2025年全球最能挣钱的药将是哪款?刚开年就锁定了候选竞争者。   2月5日,诺和诺德公布2024年业绩,以“减重功效”闻名的司美格鲁肽总收入2018.49亿丹麦克朗(约合2140亿元人民币),相当于日赚5.6亿元,距离全球“药王”仅差半步。   就在前一日,默沙东公布旗下Keytruda(下称“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10